d he will continue with full oversight and portfolio management responsibilities for NLV-I and NLV-II. Jim is currently on the boards of directors of Chimerix (NASDAQ: CMRX, former Chairman) and Tioga. He was previously on the boards of Intarcia Therapuetics (now currently a Board observer), Sirna Therapeut

Examples of these types of biopharmaceutical investments in the NLV portfolio are Array Biopharma (NLV-II, NASDAQ: ARRY, oncology, exited at 2.25x), Chimerix (NLV-IL, private initially, now public on NASDAQ: CMRX, novel anti-viral therapy), and Versartis (NLV-II, private, novel, long-acting human growth ho